Amarin | AMRN - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 3.61B 2.92B 2026-06
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amarin USD -1.22M 6.51M 2025-12
AstraZeneca USD 2.51B 573M 2026-06
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
DBV Technologies USD -47.6M 2.77M 2026-03
GlaxoSmithKline GBP 435M 1.3B 2026-06
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Novartis USD 3.26B 108M 2026-06